RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024How much of that $1.37 trillion can those top 25 biopharmas be expected to spend in 2024? Plenty enough for ONCY to be acquired.
This may bode well for the perhaps preferred deal targets of today: young startup and emerging clinical-stage companies with promising and differentiated therapies in development.
“What that means is there’s not enough [quality] pipeline in the R&D system to be able to bridge the gap that we expect the industry will have. That is a prime trigger for access to external innovation, M&A, partnership, etc.
“The FOMO (fear of missing out) factor it at work for some of the investment community . … There are a lot of considerations in driving this business and obviously there are potential big payouts, too.”